LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated genetic analyzers for pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. More Details
Excellent balance sheet and fair value.
Share Price & News
How has LexaGene Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LXG is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: LXG's weekly volatility (10%) has been stable over the past year.
7 Day Return
CA Medical Equipment
1 Year Return
CA Medical Equipment
Return vs Industry: LXG underperformed the Canadian Medical Equipment industry which returned 36% over the past year.
Return vs Market: LXG underperformed the Canadian Market which returned 37.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is LexaGene Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StWe Think LexaGene Holdings (CVE:LXG) Can Afford To Drive Business Growth
11 months ago | Simply Wall StDo Insiders Own Shares In LexaGene Holdings Inc. (CVE:LXG)?
1 year ago | Simply Wall StHere's Why We're A Bit Worried About LexaGene Holdings's (CVE:LXG) Cash Burn Situation
Is LexaGene Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: LXG (CA$0.59) is trading below our estimate of fair value (CA$9.06)
Significantly Below Fair Value: LXG is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: LXG is unprofitable, so we can't compare its PE Ratio to the XN Medical Equipment industry average.
PE vs Market: LXG is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LXG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LXG is good value based on its PB Ratio (5.3x) compared to the CA Medical Equipment industry average (7.7x).
How is LexaGene Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LexaGene Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has LexaGene Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LXG is currently unprofitable.
Growing Profit Margin: LXG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LXG is unprofitable, and losses have increased over the past 5 years at a rate of 32.3% per year.
Accelerating Growth: Unable to compare LXG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LXG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.8%).
Return on Equity
High ROE: LXG has a negative Return on Equity (-88.99%), as it is currently unprofitable.
How is LexaGene Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: LXG's short term assets ($10.1M) exceed its short term liabilities ($528.1K).
Long Term Liabilities: LXG's short term assets ($10.1M) exceed its long term liabilities ($1.4M).
Debt to Equity History and Analysis
Debt Level: LXG is debt free.
Reducing Debt: LXG has no debt compared to 5 years ago when its debt to equity ratio was 65.9%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LXG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if LXG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is LexaGene Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LXG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LXG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LXG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LXG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LXG's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. John F. Regan, also known as Jack, is the Founder of LexaGene Holdings Inc. since 2016 and has been its Chairman of the Board since September 12, 2017 and its Chief Executive Officer and Director since...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD374.84K) is above average for companies of similar size in the Canadian market ($USD156.56K).
Compensation vs Earnings: Jack's compensation has increased whilst the company is unprofitable.
Experienced Management: LXG's management team is considered experienced (3.8 years average tenure).
Experienced Board: LXG's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31%.
LexaGene Holdings Inc.'s company bio, employee growth, exchange listings and data sources
- Name: LexaGene Holdings Inc.
- Ticker: LXG
- Exchange: TSXV
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: CA$72.387m
- Shares outstanding: 118.67m
- Website: https://www.lexagene.com
Number of Employees
- LexaGene Holdings Inc.
- 500 Cummings Center
- Suite 4550
- United States
LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated genetic analyzers for pathogen detection in veterinary diagnostics, human clinical ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 22:15|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.